Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: Opportunities for pharmacologic enhancement of immunotherapy

Alisha Holtzhausen, Fei Zhao, Kathy S. Evans, Masahito Tsutsui, Ciriana Orabona, Douglas Tyler, Brent A. Hanks

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated tolerogenic DCs in promoting carcinogenesis in preclinical models. The molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood, and the methods by which developing cancers can co-opt this pathway to subvert immune surveillance are currently unknown. This work demonstrates that melanoma-derived Wnt5a ligand upregulates the durable expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme by local DCs in a manner that depends upon the β-catenin signaling pathway. These data indicate that Wnt5aconditioned DCs promote the differentiation of Tregs in an IDOdependent manner, and that this process serves to suppress melanoma immune surveillance.Wefurther show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti-CTLA-4 antibody therapy. Finally, our data suggest that β-catenin signaling activity, based on a target gene expression profile that includes IDO in human sentinel lymph node-derived DCs, is associated with melanoma disease burden and diminished progression-free survival. This work implicates the Wnt-β-catenin signaling pathway as a novel therapeutic target in the melanoma immune microenvironment and demonstrates the potential impact of manipulating DC function as a strategy for optimizing tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)1082-1095
Number of pages14
JournalCancer immunology research
Volume3
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Immunotherapy
Dendritic Cells
Catenins
Melanoma
Ligands
Immune Tolerance
Wnt Signaling Pathway
Regulatory T-Lymphocytes
Enzymes
Transferases
Transcriptome
Population
Disease-Free Survival
Cell Differentiation
Immunity
Neoplasms
Carcinogenesis
Up-Regulation
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance : Opportunities for pharmacologic enhancement of immunotherapy. / Holtzhausen, Alisha; Zhao, Fei; Evans, Kathy S.; Tsutsui, Masahito; Orabona, Ciriana; Tyler, Douglas; Hanks, Brent A.

In: Cancer immunology research, Vol. 3, No. 9, 01.09.2015, p. 1082-1095.

Research output: Contribution to journalArticle

Holtzhausen, Alisha ; Zhao, Fei ; Evans, Kathy S. ; Tsutsui, Masahito ; Orabona, Ciriana ; Tyler, Douglas ; Hanks, Brent A. / Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance : Opportunities for pharmacologic enhancement of immunotherapy. In: Cancer immunology research. 2015 ; Vol. 3, No. 9. pp. 1082-1095.
@article{b66e5f82dc0b4df5b94bdda5c273a06b,
title = "Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: Opportunities for pharmacologic enhancement of immunotherapy",
abstract = "The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated tolerogenic DCs in promoting carcinogenesis in preclinical models. The molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood, and the methods by which developing cancers can co-opt this pathway to subvert immune surveillance are currently unknown. This work demonstrates that melanoma-derived Wnt5a ligand upregulates the durable expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme by local DCs in a manner that depends upon the β-catenin signaling pathway. These data indicate that Wnt5aconditioned DCs promote the differentiation of Tregs in an IDOdependent manner, and that this process serves to suppress melanoma immune surveillance.Wefurther show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti-CTLA-4 antibody therapy. Finally, our data suggest that β-catenin signaling activity, based on a target gene expression profile that includes IDO in human sentinel lymph node-derived DCs, is associated with melanoma disease burden and diminished progression-free survival. This work implicates the Wnt-β-catenin signaling pathway as a novel therapeutic target in the melanoma immune microenvironment and demonstrates the potential impact of manipulating DC function as a strategy for optimizing tumor immunotherapy.",
author = "Alisha Holtzhausen and Fei Zhao and Evans, {Kathy S.} and Masahito Tsutsui and Ciriana Orabona and Douglas Tyler and Hanks, {Brent A.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1158/2326-6066.CIR-14-0167",
language = "English (US)",
volume = "3",
pages = "1082--1095",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance

T2 - Opportunities for pharmacologic enhancement of immunotherapy

AU - Holtzhausen, Alisha

AU - Zhao, Fei

AU - Evans, Kathy S.

AU - Tsutsui, Masahito

AU - Orabona, Ciriana

AU - Tyler, Douglas

AU - Hanks, Brent A.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated tolerogenic DCs in promoting carcinogenesis in preclinical models. The molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood, and the methods by which developing cancers can co-opt this pathway to subvert immune surveillance are currently unknown. This work demonstrates that melanoma-derived Wnt5a ligand upregulates the durable expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme by local DCs in a manner that depends upon the β-catenin signaling pathway. These data indicate that Wnt5aconditioned DCs promote the differentiation of Tregs in an IDOdependent manner, and that this process serves to suppress melanoma immune surveillance.Wefurther show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti-CTLA-4 antibody therapy. Finally, our data suggest that β-catenin signaling activity, based on a target gene expression profile that includes IDO in human sentinel lymph node-derived DCs, is associated with melanoma disease burden and diminished progression-free survival. This work implicates the Wnt-β-catenin signaling pathway as a novel therapeutic target in the melanoma immune microenvironment and demonstrates the potential impact of manipulating DC function as a strategy for optimizing tumor immunotherapy.

AB - The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated tolerogenic DCs in promoting carcinogenesis in preclinical models. The molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood, and the methods by which developing cancers can co-opt this pathway to subvert immune surveillance are currently unknown. This work demonstrates that melanoma-derived Wnt5a ligand upregulates the durable expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme by local DCs in a manner that depends upon the β-catenin signaling pathway. These data indicate that Wnt5aconditioned DCs promote the differentiation of Tregs in an IDOdependent manner, and that this process serves to suppress melanoma immune surveillance.Wefurther show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti-CTLA-4 antibody therapy. Finally, our data suggest that β-catenin signaling activity, based on a target gene expression profile that includes IDO in human sentinel lymph node-derived DCs, is associated with melanoma disease burden and diminished progression-free survival. This work implicates the Wnt-β-catenin signaling pathway as a novel therapeutic target in the melanoma immune microenvironment and demonstrates the potential impact of manipulating DC function as a strategy for optimizing tumor immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84962023214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962023214&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-14-0167

DO - 10.1158/2326-6066.CIR-14-0167

M3 - Article

C2 - 26041736

AN - SCOPUS:84962023214

VL - 3

SP - 1082

EP - 1095

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 9

ER -